Novel Technologies

Novel Technologies

Novel technologies have the potential to change inheritable blood and bleeding disorders forever. Read about gene therapy and other developments.

Hand with Gene
Assessing the My Life, Our Future Genotyping Project A recent article in the journal Haemophilia analyzed the My Life, Our...
Illustration of DNA strand
On February 23 and 24, an international group of researchers from universities, industry and government gathered in Washington, DC, for...
The Judith Graham Pool Postdoctoral Research Fellowship Program Supports Hemophilia Research Breakthroughs of the Future
All of the funding for the JGP program comes from donations from NHF chapters and individuals.
My Life, Our Future: Enrolling Through December 15, 2017
We strive toward enrolling 2,000 confirmed hemophilia carriers in the MLOF Research Repository.
A better way to treat hepatitis
Like hepatitis C, hepatitis B is a viral infection in the liver. The infection can be acute or chronic, in...
Technology allows for more precise measurement of von Willebrand factor activity
The most common inherited bleeding disorder, von Willebrand disease (VWD) has also been one of the most difficult to diagnose...
New Hemophilia Treatments: Subcutaneous Injection
Two subcutaneous therapies are currently being investigated.
My Life Our Future logo
MLOF is open to all people with hemophilia A and B.
Hemophilia Gene Therapy Comes of Age
More than 100 researchers met for NHF's 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia.
Unlocking Hemophilia
The MLOF Research Repository will allow researchers to explore long-unanswered questions about hemophilia.
New hep C drug cures major genotypes
Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6.
FVII Gene Therapy Trial in Dogs; New FIX and HCV Drugs
An update on FVII gene therapy and more.
Chat Icon
Need Info? Ask NHF!
Contact HANDI, NHF's resource center for additional information on bleeding disorders.